Loading...
Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant
Efficacy of PTCy after mismatched unrelated donor (MMUD) HCT is unknown. In this pilot clinical trial, we enrolled 38 patients with hematologic malignancies scheduled to undergo MMUD-HCT (≥6/8 HLA-matched donors) onto 1 of 2 conditioning strata: myeloablative using fludarabine and fractionated total...
Saved in:
| Published in: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society of Hematology
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8270662/ https://ncbi.nlm.nih.gov/pubmed/34156440 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2021004192 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|